ClinicalTrials.gg
Not yet recruitingNCT07872436VICTOR-DMUpdated Oct 13, 2026

A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control

A Phase 2 interventional study of VCT220 tablets and Placebo in Type 2 Diabetes Mellitus (DM), sponsored by Vincentage Pharma Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Vincentage Pharma Co., Ltd · Phase 2, Interventional, and Treatment

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
455th of 767
120 · median 199
Started
2026
with 87 others
Phase 2
61 of 909
14 open now
Primary completion
2027-07
later than 135 of 227 live
Registered
888th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 455th largest by planned enrollment of the 767 interventional ones that give a count, is one of 88 that started in 2026, is one of 61 in phase 2, reaches primary completion later than 135 of the 227 other live ones, and was the 888th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This study will evaluate whether VCT220 tablets improve blood glucose control in adults with type 2 diabetes whose blood glucose remains inadequately controlled with lifestyle intervention alone, metformin alone, or metformin combined with a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The study will also assess safety, tolerability, and how VCT220 is processed by the body.

Approximately 120 participants will be randomly assigned in equal proportions to VCT220 40 mg, 80 mg, 120 mg, or placebo, taken orally once daily for 16 weeks. Higher-dose groups will start at 40 mg and increase the dose in steps. Participation will last approximately 22 weeks, including screening, a placebo run-in period, treatment, and safety follow-up. The main assessment is the change in glycated hemoglobin (HbA1c) from baseline to Week 16.

03

Conditions studied

  • Type 2 Diabetes Mellitus (DM)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 65 years, inclusive, at the time of .
  2. Type 2 diabetes mellitus diagnosed at least 3 months before screening according to the Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 edition), and meeting one of the following: (a) management with diet and exercise alone for at least 3 months before screening; or (b) oral metformin at a stable dose of ≥1500 mg/day or a maximum tolerated dose of ≥1000 mg/day, alone or with an SGLT2 inhibitor at a stable dose, for at least 8 weeks before screening.
  3. of 7.5% to 10.5%, inclusive, at screening, as measured by the local laboratory.
  4. Body weight ≥50 kg and of 19 to 35 kg/m², inclusive.
  5. Self-reported or documented body weight change of no more than 5% within the 3 months before screening.
  6. Willing and able to maintain a stable residence, remain contactable, and maintain a regular daily routine and diet and exercise management throughout the study.
  7. Fully understands the study procedures, can communicate effectively with the investigator, understands and can comply with study requirements, and is willing to sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Previous diagnosis or suspicion of type 1 diabetes, other specific types of diabetes, or secondary diabetes.
  2. Acute complications of diabetes within 6 months before screening, including diabetic ketoacidosis, lactic acidosis, or hyperosmolar hyperglycemic state.
  3. A Level 3 hypoglycemic event or at least three hypoglycemic events within 6 months before screening.
  4. History or current presence of proliferative retinopathy or maculopathy, painful diabetic neuropathy, diabetic foot ulceration, or intermittent claudication.
  5. A hematologic disorder or other condition at screening that may affect measurement, including known hemoglobinopathy, hemolytic anemia, sickle cell anemia, blood transfusion within 3 months before screening, or severe blood loss within that period.
  6. Any of the following local laboratory or 12-lead findings during screening:

    • Fasting plasma glucose >11.1 mmol/L.
    • Thyroid-stimulating hormone >6.0 mIU/L or \<0.4 mIU/L.
    • or aspartate aminotransferase ≥2 times the (ULN), or total ≥2 × ULN.
    • Fasting triglycerides >5.65 mmol/L.
    • Serum amylase or lipase ≥1.5 × ULN.
    • Estimated \<60 mL/min/1.73 m².
    • Calcitonin ≥50 ng/L.
    • \<110 g/L in males or \<100 g/L in females.
    • Electrocardiographic heart rate \<55 or >110 beats/minute.
    • Second- or third-degree atrioventricular block, long syndrome, QTcF >450 ms in males or >470 ms in females, left bundle branch block, complete right bundle branch block, pre-excitation syndrome, or other arrhythmia, except asymptomatic sinus arrhythmia.
  7. Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening.
  8. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  9. History or current presence of severe gastrointestinal disease or relevant surgery, including acute or chronic pancreatitis, hepatitis, cholecystitis (except after cholecystectomy), or intestinal obstruction.
  10. Heart failure of Class III or IV, unstable angina, stroke, myocardial infarction, or coronary revascularization within 6 months before screening; or planned coronary, carotid, or peripheral arterial revascularization at screening.
  11. Acute infection within 2 weeks before screening.
  12. Any within the previous 5 years or currently, except cured basal cell carcinoma of the skin or cervical carcinoma in situ.
  13. History or current presence of a condition that may require repeated or long-term systemic therapy, such as systemic lupus erythematosus, inflammatory bowel disease, or asthma. Topical, intraocular, and intranasal glucocorticoids are excluded from this restriction.
  14. Known or suspected allergy to VCT220 tablets, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or .
  15. Previous discontinuation of a GLP-1 RA because of safety or tolerability concerns.
  16. Insulin treatment within 3 months before screening, or treatment with any glucose-lowering medication other than metformin or an SGLT2 inhibitor during that period, including traditional Chinese medicines used to lower blood glucose.
  17. Positive surface antigen at screening, except when quantitative hepatitis B virus DNA is below the lower limit of the assay reference range and the participant is not receiving anti-hepatitis B medication at screening; or positive virus antibody, antibody, or syphilis antibody.
  18. Significantly active or unstable major depressive disorder or another severe psychiatric disorder within 2 years before screening, or any history of attempted suicide.
  19. History of alcohol or drug abuse within 3 months before screening. Alcohol abuse is defined as more than 7 units per week; one unit is 360 mL of beer containing 5% alcohol, 45 mL of spirits containing 40% alcohol, or 150 mL of wine containing 12% alcohol.
  20. Treatment with any other product within 3 months or 5 half-lives before screening, whichever is longer, or plans to participate in another clinical trial during this study.
  21. Pregnancy or breastfeeding; a male or female participant of unwilling to use highly effective throughout the study and for 3 months after the last dose; plans to conceive or donate sperm or oocytes during that period; or a positive pregnancy test during screening.
  22. An employee of the sponsor, a study site, or the contract research organization, or an immediate family member of such an employee.
  23. Considered unsuitable for study participation by the study site.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    VCT220 40 mg

    Drug: VCT220 tablets

  • Experimental
    VCT220 80mg

    Drug: VCT220 tablets

  • Experimental
    VCT220 120mg

    Drug: VCT220 tablets

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • VCT220 tablets will be administered orally once daily for 16 weeks, preferably with the first meal of the day, according to the assigned treatment regimen and protocol-specified titration schedule. Matching placebo tablets will be added as needed to maintain blinding.

  • DrugPlacebo

    Matching placebo tablets containing no active ingredient will be administered orally once daily for 16 weeks, preferably with the first meal of the day. The number of tablets will match that used in the active treatment groups at each treatment stage to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c

    Time frame: Baseline (Week0) and Week 16

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose

    Time frame: Baseline (Week0) and Week 16

  2. Change From Baseline in Fasting Insulin

    Time frame: Baseline (Week0) and Week 16

  3. Change From Baseline in Fasting C Peptide

    Time frame: Baseline (Week0) and Week 16

  4. Change From Baseline in 2 Hour Postprandial Plasma Glucose

    Time frame: Baseline (Week0) and Week 16

  5. Change From Baseline in 2 Hour Postprandial Insulin

    Time frame: Baseline (Week0) and Week 16

  6. Change From Baseline in 2 Hour Postprandial C Peptide

    Time frame: Baseline (Week0) and Week 16

  7. Percentage of Participants With HbA1c Below 7%

    Time frame: Week 16

  8. Percentage of Participants With HbA1c at or Below 6.5%

    Time frame: Week 16

  9. Change From Baseline in Mean 7 Point Self Monitored Blood Glucose

    Time frame: Baseline (Week0) and Week 16

  10. Incidence of Adverse Events

    Time frame: From enrollment to the end of treatment at week 16

  11. VCT220 Plasma Concentration

    Time frame: Week 0、Week 2、Week 4、Week 8、Week 12 and Week 16

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 8 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2026
First posted
Oct 13, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07872436
Lead sponsor
Vincentage Pharma Co., Ltd
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Miles Zhang
Contact
bd@vincentage.com
86+18210070401

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VCT220

Start the discussion